Literature DB >> 7131307

Pirmenol hydrochloride (CI-845) and reference antiarrhythmic agents: effects on early ventricular arrhythmias after acute coronary artery ligation in anesthetized rats.

T E Mertz, H R Kaplan.   

Abstract

The coronary artery-ligated rat was investigated as an experimental model for studying the effects of pirmenol hydrochloride and reference for studying the effects of pirmenol hydrochloride and reference agents on early ventricular arrhythmias. Coronary artery ligation caused 89% lethality (ventricular fibrillation) within 10 min in untreated control rats. Vagal stimulation applied during periods of high-rate ventricular tachycardia reduced sinus, atrioventricular nodal and ventricular ectopic beats, with no uncoupled ectopic beats seen during stimulation. Rats studied with composite epicardial electrodes showed continuous electrical activity throughout diastole. These factors indicate that a reentry mechanism is likely involved. Pretreatment with pirmenol afforded protection in a dose-related fashion. A dose of 1.25 mg/kg increased survival to 58%, and all rats dosed with 2.5 to 10 mg/kg survived. Suppression of ventricular fibrillation was dose related and was complete at 5 mg/kg. The pirmenol plasma levels of 1.2 +/- 0.1 microgram/ml seen after the 5 mg/kg dose are similar to plasma levels seen at clinically effective doses, as well as at doses effective in other experimental arrhythmias. The reference agent quinidine was also highly effective in this model, all rats pretreated with 5 mg/kg survived with reduced premature ventricular beats and without a single episode of ventricular fibrillation or death. Fibrillation and/or death were also reduced by the reference agents, bretylium, lidocaine, propranolol and verapamil. The high efficacy of pirmenol against early ventricular arrhythmias in this study further defines its spectrum of activity, and suggests that pirmenol may be effective in a clinical setting where a reentrant mechanism is operative.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7131307

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  The isolated blood-perfused rat heart: an inappropriate model for the study of ischaemia- and infarction-related ventricular fibrillation.

Authors:  Hugh Clements-Jewery; David J Hearse; Michael J Curtis
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

2.  Role of peptido-leukotrienes in the genesis of early ventricular arrhythmias during acute myocardial ischaemia in rats.

Authors:  A C Chang; S Dai; C W Ogle; W M Tom
Journal:  Agents Actions       Date:  1992-03

3.  Use-dependent effects of pirmenol on Vmax and conduction in guinea-pig ventricular myocardium.

Authors:  J Hasegawa; S Hirai; N Noguchi; I Hisatome; H Kotake; H Mashiba
Journal:  Br J Pharmacol       Date:  1990-04       Impact factor: 8.739

4.  Antiarrhythmic actions of verapamil against ischaemic arrhythmias in the rat.

Authors:  M J Curtis; B A MacLeod; M J Walker
Journal:  Br J Pharmacol       Date:  1984-10       Impact factor: 8.739

5.  Effects of ranitidine and cimetidine on experimentally induced ventricular arrhythmias in anaesthetized rats.

Authors:  S Dai
Journal:  Agents Actions       Date:  1986-03

6.  A protective effect of sulphinpyrazone against coronary occlusion-induced shortening of myocardial refractory periods in the rat.

Authors:  B J Northover
Journal:  Br J Pharmacol       Date:  1986-05       Impact factor: 8.739

7.  The mechanism of action of calcium antagonists on arrhythmias in early myocardial ischaemia: studies with nifedipine and DHM9.

Authors:  M J Curtis; M J Walker
Journal:  Br J Pharmacol       Date:  1988-08       Impact factor: 8.739

Review 8.  Animal models of arrhythmia: classic electrophysiology to genetically modified large animals.

Authors:  Sebastian Clauss; Christina Bleyer; Dominik Schüttler; Philipp Tomsits; Simone Renner; Nikolai Klymiuk; Reza Wakili; Steffen Massberg; Eckhard Wolf; Stefan Kääb
Journal:  Nat Rev Cardiol       Date:  2019-08       Impact factor: 32.419

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.